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BACKGROUND: Two million people in the UK had a cancer diagnosis at the end of 2008. Understanding the number of people
diagnosed with cancer with and without health needs is valuable information that can be used to inform service planning, treatment
provision and support for people at the right time in the right place as demand grows over time.
METHODS: Using available data and clinically led assumptions about patient need and outcomes, we make indicative estimates. We
quantify, for three common cancers, the number of people in each of the five main identified phases of the cancer care pathway.
RESULTS: Estimates are provided for each phase of the pathway for breast, colorectal and lung cancers. We estimate that there are
nearly 575000 women a year with breast cancer in the care pathway at some point in the year, 8% are in the rehabilitation phase and
4% in the progressive illness phase. This compares to nearly 270000 with colorectal and around 95000 with lung cancer.
CONCLUSION: Using readily available data, we estimate the numbers of patients with different health needs. These numbers could
inform the targeting of resources for service providers.
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Two million people in the UK had a cancer diagnosis at the end of
2008; some were diagnosed the previous week, whereas others were
diagnosed more than 20 years ago (Figure 1; Maddams et al, 2009).
With 309000 new cases of cancer diagnosed in 2008, the number of
people living with cancer is rising every day (Information Services
Division (ISD) Scotland, 2010; Northern Ireland Cancer Registry,
2011; Welsh Cancer Intelligence and Surveillance Unit, 2010; Office
for National Statistics, 2010a). If current trends continue, there will
be 4 million cancer survivors (people living who have had a cancer
diagnosis at some point in their lives) by 2030 (estimated, based on
Maddams et al, 2009).
We estimate that around 245000 people died in 2008 having had
a diagnosis of cancer, of whom 64% died from their cancer and
36% died because of some other cause (see Figure 1; Information
Services Division (ISD) Scotland, 2010; Northern Ireland Cancer
Registry, 2011; Welsh Cancer Intelligence and Surveillance Unit,
2010; Maddams et al, 2009; Office for National Statistics, 2010a).
This estimate is intended to be indicative only. Given the
inaccuracies associated with death registrations and cause of
death, more accurate estimates cannot be made (Office for
National Statistics, 2010b). The estimated proportions are
consistent with similar data for South West England (South West
Public Health Observatory, Cancer Intelligence Service, 2009).
For some of these cancer survivors there may be a period of
several apparently cancer-free years before the development of
incurable metastatic disease, and then several further years living
with incurable cancer before reaching the last year of life. In
addition, cancer survivors may have treatment-related health
problems ranging from the trivial to the very complex, some of
which are amenable to intervention through secondary prevention
or detection and effective management.
Understanding the number of people diagnosed with primary and
secondary cancer is valuable information that can be used to inform
service planning, treatment provision and support for people at the
right time in the right place as demand grows over time.
Cancer survival is regularly reported, but little data are routinely
reported by cancer registries about cancer survivors. This amplifies
the assumption that cancer survivors have no particular needs
requiring specific resources. The lack of segmentation of the
population of survivors into different groups based on their need for
services has hampered the progress of the survivorship programme.
The survivorship programme (Department of Health, Macmillan
Cancer Support and NHS Improvement, 2010) aims to improve
and maintain health and well-being and reduce disability related to
cancer and its treatment. Interventions need to be targeted to
populations where they will achieve the most benefit, and
interventions that do not add value need to be replaced.
Data are currently not routinely collected to enable accurate
calculation of the numbers at different phases of the care pathway.
We therefore use available data together with clinically led
assumptions to segment the survivorship population to enable
service planning and resource allocation. We use and present these
data to stimulate interest and debate to ensure that accurate data
are collected and reported in the future.
MATERIALS AND METHODS
Using clinically led assumptions about patient need and outcomes,
and available data on cancer incidence, survival, prevalence and
mortality data, indicative estimates are made to quantify need
across the cancer care pathway. *Correspondence: H McConnell; E-mail: hmcconnell@macmillan.org.uk
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greatly and this estimation is indicative only. For example, some
people will go through all phases in the pathway, some will
experience only one or two phases, some will spend varying
amounts of time in each phase, requiring differing levels of
support and some people will not die from their cancer but may
suffer from consequences of either the disease or its treatment.
Assumptions
Five main phases on the care pathway have been identified
(Figure 2):
  diagnosis and treatment (assumed to be the year from
diagnosis),
  rehabilitation (assumed to be the year after treatment, estimated
as the second year after diagnosis),
  monitoring (includes those at risk of recurrence or treatment
complications but with no active cancer or treatment-related
illness, and is split here between early and later monitoring),
  progressive illness (includes incurable cancer, but not those in
the last year of life, and significant treatment-related illness),
  end of life (includes those in the last year of life presented with
a subset diagnosed in the same year).
T h ef l o wo fp e o p l ei n t oa n do u to fd i f f e r e n tp h a s e so ft h ep a t h w a yi s
dynamic, but our model aims to estimate the number of people in the
phases in a given year. Therefore, we assume that prevalence numbers
more than 2 years from diagnosis and counted at a point in time
reflect the stock in a year, and that incidence and mortality data
capture the flow of cancer patients into and out of survivorship phases.
Those dying from causes other than cancer have been excluded – we
estimate that in total around 90000 people with a cancer diagnosis in
the UK died from causes other than cancer in 2008 (estimated, see
Figure 1). Some of these people may in fact die from conditions related
to their cancer or from the late effect of cancer treatment; however,
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Figure 1 People newly diagnosed, people living with cancer by year
since diagnosis and deaths for people with a cancer diagnosis, UK, 2008.
a,b
aAll cancers exclude non-melanoma skin cancer (ICD-10 C44), except for
cancer deaths that include deaths from all malignancies.
bIncidence is the
number of newly diagnosed cases and is a count of tumours in 2008.
Mortality is a count of deaths due to cancer in 2008. Prevalence is a
count of the number of people living with cancer at the end of 2008.
cPrevalence measures time since diagnosis up to 1, 5, 10 or 20 years. For
example, ‘1X5 years’ means more than 1 year and up to 5 years since
diagnosis and ‘420 years’ is more than 20 years since diagnosis.
dThe
number of deaths for people with a cancer diagnosis, 245000, is estimated
assuming that the rate of increase in prevalence is 3.2% (Maddams et al,
2009) and using incidence and mortality data. Prevalence is increasing at
3.2% a year; thus, approximately 64000 people are added to the prevalent
stock at the end of 2008. The increase in prevalence (64000) is a product
of new cases and deaths. With 309000 new cases and 157000 cancer
deaths in 2008, we estimate that approximately 88000 people die
from other causes; therefore, we estimate that there were 245000
deaths for people with a cancer diagnosis. Sources: Maddams et al (2009);
Cancer Research UK (2010); Information Services Division (ISD) Scotland
(2010); Northern Ireland Cancer Registry (2011); Welsh Cancer
Intelligence and Surveillance Unit (2010); Office for National Statistics
(2010a,b).
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Figure 2 Assumptions and calculations used to estimate the cancer care pathway.
aThe numbers in the progressive illness group will be underestimated
and the numbers in the monitoring groups overestimated as estimates for significant late effects have not been made.
bWe calculate a subset of deaths in
the first year of diagnosis to clarify the risk of double counting in diagnosis and treatment and end of life care.
cUnless otherwise stated data are for 2008.
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As more data become available, we may be able to include some of
these people in the cancer care pathway.
Data and limitations
The analysis is based on the collation of available data on cancer
incidence, survival, prevalence and mortality from available
sources to provide indicative estimates as to the number of people
in each phase of the care pathway in a year.
Data for all cancers are, unless otherwise stated, for all malig-
nant neoplasms excluding non-melanoma skin cancer (ICD-10 C00-
C97 excluding C44). We estimate pathways for three cancer types:
  Breast cancer in women (ICD-10 C50),
  Colorectal cancer, which includes colon, rectum and anus
(ICD-10 C18-C21) and
  Lung cancer, which includes lung, bronchus and trachea
(ICD-10 C33-C34).
Figures 3A–C presents 2008 incidence, mortality and prevalence
data for the UK for breast, colorectal and lung cancer. These data
are used along with survival data and clinical assumptions to
estimate the pathways of care. How the data are used to quantify
the number of people in each phase is described below.
Diagnosis and treatment
Cancer incidence data are used as a proxy to estimate the number
of people requiring care, supervised and delivered by the acute
sector in the year following diagnosis. Cancer incidence data for
2008 are collected by Cancer Registries across the UK. We use
published data for each nation for England, from the Office for
National Statistics (2010a), and from the national registries of
each of the Celtic Nations ((ISD) Scotland, 2010; Welsh Cancer
Intelligence and Surveillance Unit, 2010; Northern Ireland Cancer
Registry, 2011).
Rehabilitation
If cancer survivors had rehabilitation services, such as physio-
therapy, occupational therapy, dietetics, lifestyle assessment and
planning after cancer treatment, patients could return to normal
life more quickly. For example, there is evidence that, for some
cancers, doing recommended levels of physical activity can reduce
the risk of recurrent cancer and mortality (Holmes et al, 2005;
Meyerhardt et al, 2006; Kenfield et al, 2011). On the basis of patient
questionnaires following up cancer survivors after treatment, one
study found that 30% reported five or more unmet needs at the
end of treatment, and for the majority of them (60%) the situation
had not improved 6 months later (Armes et al, 2009). We have
therefore estimated that people in this phase of the pathway are
identified as those who have survived the first year after diagnosis
and hence may require rehabilitative support in their second year
after diagnosis. Estimates are calculated using 1-year survival
(Office for National Statistics and London School of Hygiene
and Tropical Medicine, 2011) and cancer incidence from 2007 to
estimate the number of deaths in the first year. This is then
subtracted from cancer incidence in 2007 to give an estimate of
those alive in their second year after diagnosis. Rehabilitation
services could be supervised and delivered in the acute sector or
the community.
Monitoring
Prevalence data (Maddams et al, 2009) are used as a proxy to
estimate the number of people in early or later monitoring based
on time since diagnosis. Those people with ‘progressive illness’ are
excluded from the monitoring phase.
‘Early monitoring’ might be seen as the phase in which there
is no active cancer or treatment-related consequence requiring
intervention, but there is a significant risk of occurrence.
It might be expected that monitoring would be supervised by
specialists, for example, by producing a plan of tests. This could
be delivered in the community or acute sector. The period of
high risk may vary from 2 to 10 years depending on the cancer
considered.
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Figure 3 (A) Women newly diagnosed, living with breast cancer by year
since diagnosis and breast cancer deaths, UK, 2008.
a,b (B) People newly
diagnosed, living with colorectal cancer by year since diagnosis and colo-
rectal cancer deaths, UK, 2008.
a,b (C) People newly diagnosed, living with
lung cancer by year since diagnosis and lung cancer deaths, UK, 2008.
a,b
aFemale breast (ICD-10 C50). Colon, rectum and anus (ICD-10 C18-C21).
Lung, bronchus and trachea (ICD-10 C33-C34).
bIncidence is the number
of newly diagnosed cases and is a count of tumours in 2008. Mortality is a
count of deaths due to cancer in 2008. Prevalence is a count of the number
of people living with cancer at the end of 2008.
cPrevalence measures time
since diagnosis up to 1, 5, 10 or 20 years. For example, ‘1X5 years’ means
more than 1 year and up to 5 years since diagnosis and ‘420 years’ is more
than 20 years since diagnosis. The prevalence estimate for men with lung
cancer more than 20 years from diagnosis is likely be overestimated by
B8000. Sources: Maddams et al (2009); Cancer Research UK (2010);
Information Services Division (ISD) Scotland (2010); Northern Ireland
Cancer Registry (2011); Welsh Cancer Intelligence and Surveillance Unit
(2010); Office for National Statistics (2010a,b).
New pathways of care
J Maher and H McConnell
S7
British Journal of Cancer (2011) 105(S1), S5–S10 & 2011 Cancer Research UKAfter this higher-risk phase, patients may still be at a small
risk of late recurrence but may also be at continued risk of an
increase in chronic illness such as heart disease or osteoporosis
(Khan et al, 2011b), which could have been reduced through
proactive intervention. This will particularly be the case for those
treated at a younger age (Oeffinger et al, 2006). Additional
monitoring in this later phase may well be appropriate in primary
care. To illustrate the approach, we have identified as ‘early
monitoring’ those surviving up to 5 and 10, but more than 2 years
from initial diagnosis. ‘later monitoring’ identifies those surviving
10 or more years from initial diagnosis.
Progressive illness
A majority of those patients who die of cancer after the first 2 years
will die of metastatic disease. The date of the first abnormal scan is
currently not routinely collected by cancer registries. This makes it
difficult to estimate the number of people who have progressive
cancer, but are not in the last year of life, who will have particular
health needs.
We have used cancer mortality data as a proxy for the number
of people with metastatic cancer in a year. Progressive illness
will vary in length by cancer type and we use median survival
(minus one to exclude those in the last year of life) and cancer
mortality to estimate people with progressive illness. We have used
the estimate of a median survival of 2.5 years for metastatic
colorectal cancer, as this was used in the recent Department of
Health Frontier report (Frontier Economics, 2010), and clinical
consensus of a median 3 years survival for breast cancer
(remembering that those in their last year of life are excluded
from this estimate). We have not included progressive conse-
quences of treatment in this estimate, which would reduce the
numbers in the ‘monitoring’ phase and increase the numbers in
the ‘progressive illness’ phase, particularly for pelvic cancers
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Figure 4 (A) Breast cancer care pathway: estimating the number of women in the UK, 2008*. (B) Colorectal cancer care pathway: estimating the number
of people in the UK, 2008*. (C) Lung cancer care pathway: estimating the number of people in the UK, 2008*. *For each cancer type, the size of the boxes
reflects the approximate proportion of people in each phase (however, there is double counting for people who are diagnosed and die in the same year –
these numbers are indicated in brackets; i.e., ‘XX000 year 1’). Median survival for incurable disease was taken from Frontier Economics (2010) and is 3 years
for breast and 2.5 years for colorectal. Estimates for progressive illness for lung cancer have not been made. Estimates for later monitoring for lung cancer
exclude 8000 men 420 years from diagnosis. The total for men in this group was thought to be an overestimate and is likely to be nearer 6000 than the
modelled 14000 (Maddams et al, 2009). Sources: Maddams et al (2009); Office for National Statistics (2009, 2010a,b); Cancer Research UK (2010); Frontier
Economics (2010); Information Services Division (ISD) Scotland (2010); Northern Ireland Cancer Registry (2011); Welsh Cancer Intelligence and
Surveillance Unit (2010); Office for National Statistics and London School of Hygiene and Tropical Medicine (2011).
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anticipate these estimates could be refined. Estimates for
progressive illness for lung cancer have not been made.
End-of-life care
Cancer mortality data (Cancer Research UK, 2010) are used as a
proxy for the number of people requiring end-of-life care. Those
who die from cancer within a year of diagnosis will be included in
both diagnosis and treatment and end-of-life care, and we also
estimate the number of patients who die in the year following
diagnosis (as a subset of end-of-life care) to clarify the risk of
double counting in the diagnosis and treatment and end-of-life
care phases. To estimate those patients who are diagnosed and die
within the year, we use 1-year survival to estimate those who die in
the first year of diagnosis. Identification of those in the last year of
life is a key part of the draft NICE Quality Standards for End of Life
Care (NICE (forthcoming) Quality Standard on End of Life Care)
and the proposed end-of-life tariff (Hughes-Hallet et al, 2011).
The number of people who die within a year of diagnosis varies
greatly by cancer type and depends on short-term survival.
We know from other recent research that at the end of 2008 more
than a quarter of all people with a cancer diagnosis, who were in
their last year of life at that point in time, were also diagnosed
within that same year (Maddams et al, 2011).
RESULTS
Figures 4A–C provide estimates of the number of people in each
phase of the care pathway for three of the most common cancers in
the UK – breast (women only), colorectal and lung cancer. These
cancers accounted for just over 40% of new diagnoses in 2008
(Information Services Division (ISD) Scotland, 2010; Office for
National Statistics, 2010b; Welsh Cancer Intelligence and Surveil-
lance Unit, 2010; Northern Ireland Cancer Registry, 2011).
For breast cancer (Figure 4A), because of its relatively good
prognosis, the majority of women in the UK will be in a
monitoring phase during any one year. Breast cancer is the most
commonly diagnosed cancer in women in the UK, and thus each
year large numbers of women are also in the diagnosis and
treatment phase. However, as a consequence, most of these women
(44000 or around 8% of women in the year) would benefit from
rehabilitative support following treatment. A further 24000 (4%)
will have incurable disease in the year (but are not in the last year
of their life), and a relatively small proportion of women are in the
last year of their life; that is, requiring end-of-life care (2%).
The proportion of cancer survivors in the monitoring phase is
lower for colorectal and lung cancer survivors than women with
breast cancer, because of the poorer prognosis of these cancers,
particularly lung cancer.
For lung cancer (Figure 4C), the number of people in both
diagnosis and treatment and end-of-life care is substantial – 41000
and 35000 in the year. However, with poor 1-year survival for lung
cancer (around 30%; Office for National Statistics and London
School of Hygiene and Tropical Medicine, 2011), the majority of
those newly diagnosed will also be counted in our end-of-life
mortality figures (estimated here as 28000 of the 35000 dying in
the year).
The data also demonstrate that people with a lung cancer
diagnosis do survive; thus, there are still, albeit lower numbers
than breast and colorectal survivors, many people diagnosed
requiring rehabilitative services (12000) and a significant number
of people who do survive up to 5, 10 and 20 years beyond initial
diagnosis (Figures 3C and 4C).
Given that the majority of people dying of lung cancer do so in
the first year following diagnosis (Office for National Statistics and
London School of Hygiene and Tropical Medicine, 2011), we have
not estimated progressive illness but we assume that as treatments
improve there will be an increasing number of survivors who will
be in progressive illness for incurable disease.
Figure 4B shows the pathway for people with a colorectal cancer
diagnosis. Colorectal cancer has a poorer prognosis than breast
cancer but much better survival than for those with lung cancer. The
5-year survival for colorectal cancer is over 50% compared with less
than 10% for men and women with lung cancer and over 80% for
women with breast cancer (Office for National Statistics and London
School of Hygiene and Tropical Medicine, 2011). Our phases clearly
reflect this pattern, with the number of women in the breast cancer
monitoring phases higher in both proportion and volume.
The third most commonly diagnosed cancer in the UK in
2008 was colorectal cancer (Information Services Division (ISD)
Scotland, 2010; Office for National Statistics, 2010b; Welsh Cancer
Intelligence and Surveillance Unit, 2010; Northern Ireland Cancer
Registry, 2011). The number of people in diagnosis and treatment
for colorectal cancer is therefore slightly lower than that for lung
cancer, 40000 compared with 41000. With its much better
prognosis, the number of people in rehabilitation is much higher
than that for lung cancer at 28000. We estimate that nearly 170000
people will be in the monitoring phase of our pathway, with most
of these in ‘early monitoring’ (57%).
We know that cancer survivors can have cancer or non-cancer-
related health problems many years after initial diagnosis. A study
presenting provisional results for colorectal cancer, which aims to
map the cancer patient’s journey by looking at patients’ hospital
inpatient activity, shows that nearly two-thirds of colorectal cancer
patients still alive between 5 and 7 years after their diagnosis were
identified as having ongoing health problems both related or
unrelated to their cancer diagnosis (Wells et al, 2011).
DISCUSSION
A key part of the charity Macmillan Cancer Support’s survivorship
approach (Department of Health, Macmillan Cancer Support and
NHS Improvement, 2010) is to identify those who are at risk of
disability or disruption to productive lives as a result of cancer and
its treatment and to intervene. Understanding the number of
people diagnosed with cancer and their position in the pathway is
valuable information that can be used to inform service planning,
treatment provision and support for people at the right time in the
right place as demand grows over time.
Cancer survivors have ongoing, unmet, needs. Up to 10 years
after diagnosis, those patients with breast and colorectal cancer are
more likely to visit their GP than people without a cancer diagnosis
(Khan et al, 2011a). Cancer survivors can spend significant amounts
of time in hospital many years after diagnosis (Maddams et al,
2011). With increasing survival, it is likely that more people will
suffer from consequences of their cancer treatment in later years.
The current focus of cancer care is on initial diagnosis and
treatment and the last year of life. There is an assumption that the
remaining group of cancer survivors has either no health-care needs
or the same health-care needs as each other and the rest of the
population. Consequently, the majority of people with a cancer
diagnosis may not be identified by health providers as requiring
support. We estimate that this current focus could exclude the
majority of women with breast cancer and people with colorectal
cancer, as well as a significant proportion of people with lung cancer.
CONCLUSION
This is the first attempt to use readily available data to segment the
population living with cancer into needs-based phases to allow
targeting of interventions and redistribution of resources. We have
modelled three tumour groups to illustrate the potential utility of
presenting data in this way. We believe the data are directionally
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other cancers.
These data convey the critical need for the development of
survivorship services and shows the survivorship population as
needs-based phases that will allow targeting of interventions and
redistribution of resources. We know that the number of people
living with cancer is increasing and, if current trends continue, is
set to double by 2030 (estimated, based on Maddams et al, 2009).
To ensure that we have services and resources to meet this
increasing demand, we need to make sure that we are effectively
targeting those in need when they need support to help them
recover, identify late effects early and die well.
Further work is needed to break down the phases; this work
could include, for example, quantifying more precisely the time at
which patients start and finish treatment and the number of people
requiring support for specific long-term effects.
New data sources within the cancer intelligence community, such
as the chemotherapy data set, which is currently in development
(National Cancer Intelligence Network, 2011a), and the radiotherapy
data set (National Cancer Services Analysis Team, 2011), may
provide more detail in the future. The National Cancer Dataset
Project (National Cancer Intelligence Network, 2011b) and other
initiatives that link data sets will make it possible to break down our
identified phases of the care pathway in more detail in the future to
ensure that we can tailor our interventions most effectively.
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